# Ionis Pharmaceuticals, Inc. (IONS) FY2026 YTD Q2 P&L / Income Statement

- Company: Ionis Pharmaceuticals, Inc. (IONS)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-07-29, accession number 0000874015-26-000251
- Page: https://plicit.ai/financials/ions/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/ions-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 514,042,000 US dollars
- **Cost of sales**: 5,721,000 US dollars
- **Gross profit (calculated)**: 508,321,000 US dollars
- **Operating expenses (calculated)**: 728,035,000 US dollars
- **Income (loss) from operations**: negative 219,714,000 US dollars
- **Other income (expense), net (calculated)**: 14,022,000 US dollars
- **Income (loss) before income tax benefit (expense)**: negative 205,692,000 US dollars
- **Income tax benefit (expense)**: 1,482,000 US dollars
- **Net income (loss)**: negative 207,174,000 US dollars
- **Product Sales, Net**: 74,094,000 US dollars
- **Royalty Revenue**: 134,282,000 US dollars
- **Other Commercial Revenue**: 18,058,000 US dollars
- **Collaborative Agreement Revenue**: 253,797,000 US dollars
- **WAINUA Joint Development Revenue**: 33,811,000 US dollars
- **Research, development and patent**: 427,280,000 US dollars
- **Selling, general and administrative**: 300,755,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Arrangement

- Page: https://plicit.ai/financials/ions/fy2026-ytd-q2-income-statement/revenue-by-arrangement
- Chart image: https://plicit.ai/charts/ions-fy2026-ytd-q2-revenue-by-arrangement-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 514,042,000 US dollars
- **Cost of sales**: 5,721,000 US dollars
- **Gross profit (calculated)**: 508,321,000 US dollars
- **Operating expenses (calculated)**: 728,035,000 US dollars
- **Income (loss) from operations**: negative 219,714,000 US dollars
- **Other income (expense), net (calculated)**: 14,022,000 US dollars
- **Income (loss) before income tax benefit (expense)**: negative 205,692,000 US dollars
- **Income tax benefit (expense)**: 1,482,000 US dollars
- **Net income (loss)**: negative 207,174,000 US dollars
- **Biogen**: 195,552,000 US dollars
- **Glaxo Smith Kline Collaboration Member**: 30,000,000 US dollars
- **Ono**: 23,805,000 US dollars
- **Otsuka**: 29,318,000 US dollars
- **Recordati**: 21,080,000 US dollars
- **Roche**: 50,000,000 US dollars
- **Undisclosed (calculated)**: 164,287,000 US dollars
- **Research, development and patent**: 427,280,000 US dollars
- **Selling, general and administrative**: 300,755,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.